Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
复制标题
DOI：
10.1111/cas.12771
复制
发表时间：
2015-11
期刊：
影响因子：
5.7
通讯作者：
Nishio M
中科院分区：
文献类型：
--
作者：
Saga T;Inubushi M;Koizumi M;Yoshikawa K;Zhang MR;Tanimoto K;Horiike A;Yanagitani N;Ohyanagi F;Nishio M
本研究评估了使用18F‐氟唑霉素阿拉伯糖（FAZA）的正电子发射断层扫描/计算机断层扫描（PET/CT）对晚期非小细胞肺癌（NSCLC）患者的预后价值，并与18F‐氟脱氧葡萄糖（FDG）进行了比较。38例晚期NSCLC患者（III期23例，IV期15例）在治疗前接受FAZA和FDG PET/CT检查。比较原发性病变和淋巴结（LN）转移的PET参数（FAZA在1和2小时的肿瘤与肌肉的比值[T/M]， FDG的最大标准化摄取值）和临床参数对无进展生存期（PFS）和总生存期（OS）的影响。在我们对所有患者的单因素分析中，临床分期和1和2 h的FAZA T/M可预测PFS （P分别= 0.021、0.028和0.002）。多因素分析还表明，临床分期和1、2 h FAZA T/M是PFS的独立预测因子。化疗III期患者的亚组分析显示，仅FAZA在2 h时的T/M可预测PFS （P = 0.025）。FDG PET/CT参数不能预测PFS。没有任何参数是OS的显著预测因子。在晚期非小细胞肺癌患者中，FAZA在LNs中的摄取可预测治疗结果，而非原发性病变。这些结果提示在晚期非小细胞肺癌患者中淋巴结转移特征的重要性。
This study evaluated the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F‐fluoroazomycin arabinoside (FAZA) in patients with advanced non‐small‐cell lung cancer (NSCLC) compared with 18F‐fluorodeoxyglucose (FDG). Thirty‐eight patients with advanced NSCLC (stage III, 23 patients; stage IV, 15 patients) underwent FAZA and FDG PET/CT before treatment. The PET parameters (tumor‐to‐muscle ratio [T/M] at 1 and 2 h for FAZA, maximum standardized uptake value for FDG) in the primary lesion and lymph node (LN) metastasis and clinical parameters were compared concerning their effects on progression‐free survival (PFS) and overall survival (OS). In our univariate analysis of all patients, clinical stage and FAZA T/M in LNs at 1 and 2 h were predictive of PFS (P = 0.021, 0.028, and 0.002, respectively). Multivariate analysis also indicated that clinical stage and FAZA T/M in LNs at 1 and 2 h were independent predictors of PFS. Subgroup analysis of chemoradiotherapy‐treated stage III patients revealed that only FAZA T/M in LNs at 2 h was predictive of PFS (P = 0.025). The FDG PET/CT parameters were not predictive of PFS. No parameter was a significant predictor of OS. In patients with advanced NSCLC, FAZA uptake in LNs, but not in primary lesions, was predictive of treatment outcome. These results suggest the importance of characterization of LN metastases in advanced NSCLC patients.